MX350011B - Composiciones terapeuticas que contienen macitentan. - Google Patents

Composiciones terapeuticas que contienen macitentan.

Info

Publication number
MX350011B
MX350011B MX2011001625A MX2011001625A MX350011B MX 350011 B MX350011 B MX 350011B MX 2011001625 A MX2011001625 A MX 2011001625A MX 2011001625 A MX2011001625 A MX 2011001625A MX 350011 B MX350011 B MX 350011B
Authority
MX
Mexico
Prior art keywords
compositions containing
therapeutic compositions
compound
containing macitentan
macitentan
Prior art date
Application number
MX2011001625A
Other languages
English (en)
Other versions
MX2011001625A (es
Inventor
Clozel Martine
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41346591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX350011(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MX2011001625A publication Critical patent/MX2011001625A/es
Publication of MX350011B publication Critical patent/MX350011B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se relaciona con un producto que contiene un compuesto de fórmula (I) a continuación (Ver fórmula (I)) o una sal farmacéuticamente aceptable de este compuesto, en combinación con al menos un compuesto que tiene propiedades de agonista del receptor prostaciclina (IP), o una sal farmacéuticamente aceptable del mismo.
MX2011001625A 2008-08-13 2009-08-12 Composiciones terapeuticas que contienen macitentan. MX350011B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2008053252 2008-08-13
PCT/IB2009/053553 WO2010018549A2 (en) 2008-08-13 2009-08-12 Therapeutic compositions containing macitentan

Publications (2)

Publication Number Publication Date
MX2011001625A MX2011001625A (es) 2011-03-29
MX350011B true MX350011B (es) 2017-08-22

Family

ID=41346591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011001625A MX350011B (es) 2008-08-13 2009-08-12 Composiciones terapeuticas que contienen macitentan.

Country Status (29)

Country Link
US (3) US8809334B2 (es)
EP (2) EP2315587B1 (es)
JP (3) JP5764061B2 (es)
KR (1) KR101678699B1 (es)
CN (1) CN102099026B (es)
AR (1) AR073031A1 (es)
AU (1) AU2009280843B2 (es)
BR (1) BRPI0917661B8 (es)
CA (1) CA2731370C (es)
CY (2) CY1119826T1 (es)
DK (2) DK3300729T3 (es)
ES (2) ES2763176T3 (es)
HK (1) HK1253355B (es)
HR (2) HRP20171917T1 (es)
HU (2) HUE047767T2 (es)
IL (1) IL211143A0 (es)
LT (2) LT2315587T (es)
MA (1) MA32614B1 (es)
MX (1) MX350011B (es)
MY (1) MY178894A (es)
NO (1) NO2315587T3 (es)
NZ (1) NZ591601A (es)
PL (2) PL3300729T3 (es)
PT (2) PT3300729T (es)
RU (1) RU2519161C2 (es)
SI (2) SI3300729T1 (es)
TW (1) TWI446911B (es)
WO (1) WO2010018549A2 (es)
ZA (1) ZA201101900B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101262847B (zh) 2005-09-12 2010-11-24 埃科特莱茵药品有限公司 包含嘧啶-磺酰胺的稳定性医药组合物
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
CN101959868A (zh) 2008-02-28 2011-01-26 日本新药株式会社 纤维化抑制剂
EP2315587B1 (en) 2008-08-13 2017-10-25 Actelion Pharmaceuticals Ltd. Therapeutic compositions containing macitentan
ES2927844T3 (es) 2013-01-11 2022-11-11 Corsair Pharma Inc Profármacos de treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9794795B1 (en) 2016-04-29 2017-10-17 Corning Optical Communications Wireless Ltd Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS
AU2017378409A1 (en) 2016-12-14 2019-07-04 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
JOP20210153A1 (ar) 2018-12-21 2023-01-30 Actelion Pharmaceuticals Ltd تركيبة صيدلانية لعلاج ارتفاع ضغط الدم الشرياني الرئوي
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1097239A (en) * 1976-05-11 1981-03-10 Salvador Moncada Enzymatic preparation of prostacyclin and its salts
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
JPS58124778A (ja) * 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
US4683330A (en) 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
ES2260318T3 (es) * 2000-12-18 2006-11-01 Actelion Pharmaceuticals Ltd. Nuevas sulfamidas y su utilizacion como antagonistas del receptor de endotelina.
BR0115995A (pt) * 2000-12-19 2004-01-13 Merck Patent Gmbh Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina
DE10100426B4 (de) 2001-01-08 2006-04-06 Steag Hamatech Ag Verfahren und Vorrichtung zum Zusammenfügen von Substraten
TWI316055B (es) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2004017993A1 (en) 2002-08-12 2004-03-04 Actelion Pharmaceuticals Ltd Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
BR0316724A (pt) * 2002-12-02 2005-10-18 Actelion Pharmaceuticals Ltd Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas
US20050101608A1 (en) 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
TW200628467A (en) * 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
CN101262847B (zh) 2005-09-12 2010-11-24 埃科特莱茵药品有限公司 包含嘧啶-磺酰胺的稳定性医药组合物
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
US8541433B2 (en) * 2008-02-20 2013-09-24 Actelion Pharmaceuticals, Ltd. Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
EP2315587B1 (en) 2008-08-13 2017-10-25 Actelion Pharmaceuticals Ltd. Therapeutic compositions containing macitentan

Also Published As

Publication number Publication date
KR20110045006A (ko) 2011-05-03
SI3300729T1 (sl) 2020-02-28
MX2011001625A (es) 2011-03-29
EP3300729A1 (en) 2018-04-04
ES2763176T3 (es) 2020-05-27
CN102099026B (zh) 2012-08-29
HUE036071T2 (hu) 2018-06-28
TWI446911B (zh) 2014-08-01
JP5764061B2 (ja) 2015-08-12
US9597331B2 (en) 2017-03-21
JP5956026B2 (ja) 2016-07-20
AU2009280843B2 (en) 2015-03-05
WO2010018549A3 (en) 2010-07-29
ES2652590T3 (es) 2018-02-05
CA2731370A1 (en) 2010-02-18
US9173881B2 (en) 2015-11-03
CY1122641T1 (el) 2021-03-12
ZA201101900B (en) 2012-08-29
PL2315587T3 (pl) 2018-03-30
NO2315587T3 (es) 2018-03-24
WO2010018549A2 (en) 2010-02-18
LT2315587T (lt) 2018-01-10
CY1119826T1 (el) 2018-06-27
RU2011109084A (ru) 2012-09-20
DK2315587T3 (en) 2018-01-02
KR101678699B1 (ko) 2016-11-23
RU2519161C2 (ru) 2014-06-10
MA32614B1 (fr) 2011-09-01
EP3300729B1 (en) 2019-10-09
PL3300729T3 (pl) 2020-04-30
EP2315587B1 (en) 2017-10-25
TW201010985A (en) 2010-03-16
HRP20171917T1 (hr) 2018-02-09
DK3300729T3 (da) 2020-01-20
EP2315587A2 (en) 2011-05-04
CA2731370C (en) 2017-03-14
IL211143A0 (en) 2011-04-28
HK1253355B (zh) 2020-06-19
AR073031A1 (es) 2010-10-06
HUE047767T2 (hu) 2020-05-28
BRPI0917661B1 (pt) 2019-12-17
US20110136818A1 (en) 2011-06-09
NZ591601A (en) 2012-12-21
US20160022678A1 (en) 2016-01-28
CN102099026A (zh) 2011-06-15
BRPI0917661A2 (pt) 2015-12-01
BRPI0917661B8 (pt) 2021-05-25
JP5956025B2 (ja) 2016-07-20
MY178894A (en) 2020-10-21
HRP20192204T1 (hr) 2020-03-06
US20140329824A1 (en) 2014-11-06
JP2015180683A (ja) 2015-10-15
LT3300729T (lt) 2020-01-10
JP2015187148A (ja) 2015-10-29
PT3300729T (pt) 2020-01-20
PT2315587T (pt) 2018-01-31
AU2009280843A1 (en) 2010-02-18
HK1253355A1 (zh) 2019-06-14
US8809334B2 (en) 2014-08-19
JP2011530581A (ja) 2011-12-22
SI2315587T1 (en) 2018-04-30

Similar Documents

Publication Publication Date Title
MY178894A (en) Therapeutic compositions containing macitentan
UA94833C2 (en) Substituted bicyclolactams
MY146924A (en) Substituted imidazoheterocycles
MX2012003389A (es) Moduladores de gpr40 de pirrolidina.
TN2011000222A1 (en) Melanocortin receptor agonists
WO2012030927A3 (en) Modified-release dosage forms of 5-ht2c agonists useful for weight management
TW200612958A (en) Substituted imidazole derivatives
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
MX2010008993A (es) Derivados de 2-aza-biciclo-[2.2.1]heptano.
TW200833328A (en) 2-aza-bicyclo[3.1.0]hexane derivatives
MX2009007077A (es) Analogos de ciclopamina.
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
HK1158192A1 (en) Piperidine gpcr agonists
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
HK1157329A1 (en) Piperidinyl gpcr agonists
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
MX2009010552A (es) Antagonistas de receptor de opioide periferico y usos de los mismos.
TW200942524A (en) Novel aminomethyl benzene derivatives
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
MX2009008028A (es) Agentes antiparasitarios.
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
EP2238105A4 (en) NOVEL COMPOUNDS, ISOMERS, OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF, CONTAINING VANILLOID RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS THEREWITH
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines

Legal Events

Date Code Title Description
FG Grant or registration